Graftcept Tablet

Introduction

Graftcept Tablet 500 mg is an immunosuppressive medication commonly used to prevent organ rejection following kidney, heart, or liver transplants. It is also used to treat certain autoimmune diseases. The drug works by suppressing the immune system to prevent the body from attacking the transplanted organ or its own tissues in autoimmune conditions.

Uses

Graftcept Tablet 500 mg is primarily used for:

Preventing organ rejection in kidney, heart, or liver transplant recipients.
Treating autoimmune diseases such as lupus nephritis and rheumatoid arthritis, often in combination with other immunosuppressants.

It is generally used in combination with other medications, such as corticosteroids or calcineurin inhibitors, to enhance its effectiveness in preventing organ rejection.

Brand Name	Graftcept
Type	Tablet
Weight	500 mg
Generic	Mycophenolate Mofetil
Manufacturer	Healthcare Pharmaceuticals Ltd.
Available in	English বাংলা

Mechanism of Action

Graftcept Tablet 500 mg works by inhibiting the enzyme inosine monophosphate dehydrogenase (IMPDH), which is crucial for the de novo synthesis of purines in lymphocytes. By blocking this enzyme, Graftcept Tablet 500 mg impairs lymphocyte proliferation and function, thus suppressing the immune response and preventing rejection of the transplanted organ or reducing autoimmune activity.

How Long Does It Take to Work?

Graftcept Tablet 500 mg may take several weeks to months to show its full therapeutic effects. Initial signs of improvement in organ transplant settings may be observed within 2-4 weeks, but the full impact on immune suppression and disease management can take longer to assess.

Absorption

Graftcept Tablet 500 mg is rapidly absorbed after oral administration. It is converted to its active form, mycophenolic acid, in the body. Peak plasma concentrations of mycophenolic acid are usually reached within 1-2 hours after ingestion of the medication.

Route of Elimination

Graftcept Tablet 500 mg and its active metabolite, mycophenolic acid, are primarily eliminated through the urine. The drug is metabolized in the liver, and renal excretion is the major route of elimination.

Dosage

Transplant patients:
Standard dosage for prophylaxis of renal rejection

Adults: A dose of 1 g administered orally twice a day (daily dose of 2 g) is recommended for use in renal transplant patients.
Children (aged 3 months to 18 years): Patients with a body surface area of 1.25 to 1.5 m² may be prescribed Mycophenolate Mofetil Tablets at a dose of 750 mg twice daily (1.5 g daily dose). Patients with a body surface area >1.5 m² may be prescribed Mycophenolate Mofetil tablets at a dose of 1 gm twice daily (2 g daily dose).

Standard dosage for prophylaxis of cardiac rejection-

Adults: A dose of 1.5 g administered orally (over not less than 2 hour) twice a day (daily dose of 3 g) is recommended for use in cardiac transplant patients.
Children: no data are available for pediatric cardiac transplant patients.

Standard dosage for prophylaxis of hepatic rejection-

Adults: A dose of 1.5 g orally twice a day (daily dose of 3 g) is recommended for use in hepatic transplant patients
Children: no data are available for pediatric hepatic transplant patients.

Standard dosage for treatment of first or refractory renal rejection-

Adults: A dose of 1.5 g administered orally twice a day (daily dose of 3 g) is recommended for management of first or refractory rejection.
Children: no data are available for the treatment of first or refractory renal rejection in pediatric renal transplant patients.

Lupus nephritis patients:
Standard Dosage for Induction Therapy-

Adults: A dose of 750 mg-1.5 g administered orally twice a day (daily dose of up to 3 g) is recommended
Children: A dose of 600 mg/m² administered orally twice a day (up to a maximum of 2 g daily) is recommended

Standard Dosage for Maintenance Therapy-

Adults: A dose of 500 mg-1 g administered orally twice a day is recommended
Children: A dose of 300 mg/m² administered orally twice a day is recommended

Mycophenolate Mofetil should be used in combination with corticosteroids. Doses should be introduced gradually and adjusted according to clinical response. Therapeutic drug monitoring could help prevent sub-therapeutic exposure (Cmin≥3.0 mg/L or inter-dose AUC ≥35 h*mg/L).

The dosage of Graftcept Tablet 500 mg varies depending on the condition being treated and patient-specific factors. Typical dosages include:

For organ transplant prevention: 1 gram twice daily for adults, or 600 mg/m² twice daily for pediatric patients.
For autoimmune diseases: 500 mg to 1 gram twice daily for adults, with adjustments based on patient response and tolerability.

Dosage adjustments may be required based on renal function and concurrent medications.

Administration

Graftcept Tablet 500 mg is administered orally in the form of tablets or capsules. It is typically taken on an empty stomach, at least 1 hour before or 2 hours after meals. It is important to take the medication consistently and at the same time each day to maintain stable drug levels in the body.

Side Effects

Common side effects include gastrointestinal symptoms such as nausea, vomiting, diarrhea, and abdominal pain. Other side effects may include headache, dizziness, and increased susceptibility to infections. Serious side effects can include bone marrow suppression, liver toxicity, and gastrointestinal bleeding.

Toxicity

Signs of toxicity may include severe gastrointestinal symptoms, infections, and significant blood count abnormalities such as anemia or leukopenia. In case of suspected toxicity, the medication should be discontinued, and appropriate medical management should be initiated.

Precautions

Graftcept Tablet 500 mg should be used with caution in patients with a history of gastrointestinal disease, renal impairment, or those at high risk of infections. Regular monitoring of blood counts and kidney function is essential to detect and manage potential adverse effects.

Interaction

Graftcept Tablet 500 mg may interact with other medications, including those affecting its absorption or metabolism. It is important to inform healthcare providers of all concurrent medications, including over-the-counter drugs and supplements, to avoid potential interactions.

Disease Interaction

Patients with a history of gastrointestinal disease, renal impairment, or a high risk of infections should use Graftcept Tablet 500 mg with caution. It is also important to monitor for signs of malignancy, as immunosuppressive therapy can increase the risk of certain cancers.

Drug Interaction

Drug interactions may occur with medications such as antacids, which can affect the absorption of Graftcept Tablet 500 mg, and other immunosuppressive drugs that can increase the risk of adverse effects. It is crucial to review all medications with a healthcare provider to manage potential interactions effectively.

Food Interactions

There are no significant food interactions with Graftcept Tablet 500 mg, but it is generally recommended to take the medication on an empty stomach to maximize absorption. Patients should follow dietary recommendations provided by their healthcare provider.

Pregnancy Use

Graftcept Tablet 500 mg is classified as Category D in pregnancy, indicating positive evidence of human fetal risk. It should only be used during pregnancy if the potential benefits outweigh the risks. Effective contraception is required during treatment and for a period after discontinuation.

Lactation Use

Graftcept Tablet 500 mg is excreted in breast milk, and its use during lactation is generally not recommended. Nursing mothers should discuss alternative treatments with their healthcare provider to ensure the safety of both mother and infant.

Acute Overdose

Acute overdose of Graftcept Tablet 500 mg may result in severe gastrointestinal symptoms, bone marrow suppression, and liver toxicity. Immediate medical attention is necessary for managing overdose and mitigating adverse effects.

Contraindication

Graftcept Tablet 500 mg is contraindicated in patients with known hypersensitivity to the drug or its components. It is also contraindicated during pregnancy and in breastfeeding mothers unless absolutely necessary.

Use Direction

Patients should follow the prescribed dosage and administration instructions provided by their healthcare provider. It is important to take the medication consistently and report any adverse effects or symptoms to the healthcare provider promptly.

Storage Conditions

Graftcept Tablet 500 mg should be stored at room temperature, away from moisture and heat. The medication should be kept in its original container and out of reach of children. Unused or expired medication should be disposed of according to local regulations.

Volume of Distribution

The volume of distribution for Graftcept Tablet 500 mg is approximately 3-4 L/kg, indicating extensive distribution throughout the body tissues and fluids.

Half Life

The half-life of Graftcept Tablet 500 mg is approximately 16-17 hours for the active metabolite mycophenolic acid. The drug's effects typically last longer due to its sustained immunosuppressive activity.

Clearance

Graftcept Tablet 500 mg is primarily cleared through renal excretion. The clearance rate can be affected by renal function, and dose adjustments may be necessary for patients with renal impairment.

See in details version Graftcept Tablet 500 mg also Graftcept Tablet 500 mg in bangla